Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop

References

• Fu M, Wang C, Li Z, et al. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439–5447.
   PubMed Web of Science ®Google Scholar
• Albero R, Enjuanes A, Demajo S, et al. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. J Clin Invest. 2018;128:4132–4147.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–762.
   PubMed Web of Science ®Google Scholar
• Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250–18255.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Lee BJ, Li C, et al. Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia. 2015;29:1414–1424.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Wang J, Sprinzen L, et al. Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. eLife. 2016;5:e14709.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Wang Y, Jiang W, et al. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J Cell Biol. 2012;198:305–313.
   PubMed Web of Science ®Google Scholar
• Daniel JA, Pellegrini M, Lee B-S, et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol. 2012;198:295–304.
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17:1374–1382.
   PubMed Web of Science ®Google Scholar
• Wasik AM, Wu C, Mansouri L, et al. Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma. Blood Adv. 2018;2:621–625.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Akiyama T, Monobe Y, et al. Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma. Mod Pathol. 2010;23:439–449.
   PubMed Web of Science ®Google Scholar
• Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7:38180–38190.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007;09:5439–5446.
   Google Scholar
• Cerhan JR, Link BK, Habermann TM, et al. Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) Cohort Study. Int J Epidemiol. 2017;46:1753–1754i.
   PubMed Web of Science ®Google Scholar
• Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta. 2014;1839:676–685.
   PubMed Web of Science ®Google Scholar
• Sanchez R, Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel. 2009;12:659–665.
   PubMedGoogle Scholar
• Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 2013;190:3670–3678.
   PubMed Web of Science ®Google Scholar
• Bea S, Amador V. Role of SOX11 and genetic events cooperating with Cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. 2017;19:43.
   PubMed Web of Science ®Google Scholar
• Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;116:167–179.
   PubMed Web of Science ®Google Scholar
• Regan PL, Jacobs J, Wang G, et al. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol. 2011;38:105–112.
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19 + CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412–2424.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89:E223–E227.
   PubMed Web of Science ®Google Scholar
• Dong W, Keibler MA, Stephanopoulos G. Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis. Metab Eng. 2017;43:113–124.
   PubMed Web of Science ®Google Scholar
• Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481:380–384.
   PubMed Web of Science ®Google Scholar
• Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–1035.
   PubMed Web of Science ®Google Scholar
• Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.
   PubMed Web of Science ®Google Scholar
• Shah B, Zhao X, Silva AS, et al. Resistance to ibrutinib in B cell malignancies: one size does not fit all. Trends Cancer. 2018;4:197–206.
   PubMed Web of Science ®Google Scholar
• Silva A, Silva MC, Sudalagunta P, et al. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 2017;77:3336–3351.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquieres H, Link BK, et al. Diagnosis to treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603–1610.
   PubMed Web of Science ®Google Scholar
• Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029–4038.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Flowers CR. Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2015;1:481–487.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Campo E, Hermine O, ESMO Guidelines Working Group, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21:1479–1487.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273–281.
   PubMed Web of Science ®Google Scholar
• Drach J, Huang H, Samoilova O, et al. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Leuk Lymphoma. 2018;59:896–903.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the european mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338–1346.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network, et al. A new prognostic index (MIPI) for patients with advanced‐stage mantle cell lymphoma. Blood. 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Scott DW, Abrisqueta P, Wright GW, Lymphoma/Leukemia Molecular Profiling Project, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35:1668–1677.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Clot G, Jares P, Giné E, et al. A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma. Blood. 2018;132:413–422.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Dreyling M. European Mantle Cell Lymphoma Network. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? Haematologica. 2017;102:1133–1136.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679–3687.
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547–555.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.
   PubMed Web of Science ®Google Scholar
• Schroers-Martin JG, Kurtz DM, Soo J, et al. Determinants of circulating tumor DNA levels across lymphoma histologic subtypes. Poster presented at The American Society of Hematology Annual Conference; 2017; Atlanta, Georgia, USA. Blood. 2017;130:4018.
   Web of Science ®Google Scholar
• Khodadoust MS, Olsson N, Wagar LE, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543:723–727.
   PubMed Web of Science ®Google Scholar
• Chen RW, Li H, Bernstein SH, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176:759–769.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–575.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–362.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410–418.
   PubMed Web of Science ®Google Scholar
• Hoster E. Long term follow-up results of rituximab maintenance in elderly MCL patients after first-line immunochemotherapy. Poster #153 presented at The American Society of Hematology Annual Conference; 2017; Atlanta, Georgia, USA.
   Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–1260.
   PubMed Web of Science ®Google Scholar